NCT05502393 is a Phase 1 clinical trial of JS107 in Advanced Solid Tumors, sponsored by Shanghai Junshi Bioscience Co., Ltd..

Who is sponsoring NCT05502393?

NCT05502393 is sponsored by Shanghai Junshi Bioscience Co., Ltd..

What drugs are being tested in NCT05502393?

Interventions in NCT05502393: JS107, Toripalimab.

What condition does NCT05502393 study?

NCT05502393 studies Advanced Solid Tumors.

Is NCT05502393 still recruiting?

NCT05502393 is currently status unknown. Last updated 16 August 2022.

Last reviewed 2022-08-16 · How we verify

NCT05502393

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors

Status unknown Phase 1 Last updated 16 August 2022

What this trial tests

Phase 1 trial testing JS107 in Advanced Solid Tumors in 118 participants. Status unknown.

Timeline

26 July 2022

Primary endpoint
31 July 2024

31 December 2024

Quick facts

Lead sponsor	Shanghai Junshi Bioscience Co., Ltd.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	118
Start date	26 July 2022
Primary completion	31 July 2024
Estimated completion	31 December 2024
Sites	3 locations across China

Drugs / interventions tested

JS107 — full drug profile →
Toripalimab (TORIPALIMAB) — full drug profile →

Conditions studied

Advanced Solid Tumors — all drugs for Advanced Solid Tumors →

Sponsor

Shanghai Junshi Bioscience Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS107 monotherapy and combination with Toripalimab in patients with Advanced or Metastatic Solid Tumors.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Future Landscape of Anti-Claudin 18.2 Antibodies in Gastric Adenocarcinoma.
Covert WM, Rogers JE. · · 2025 · cited 3× · PMID 40136475 · DOI 10.3390/antib14010026
Immuno-cytotoxic convergence: integrating antibody‒drug conjugates and immunofusion proteins to overcome resistance in gastrointestinal cancers.
Wu S, Cui R, Zhao K, Yang Z, et al · · 2026 · cited 1× · PMID 41947238 · DOI 10.1186/s13045-026-01795-6
Claudin18.2 positive gastric cancer: biology, tumor microenvironment, and therapeutic strategies.
Xie Y, Guan P, Liu D, Peng Z, et al · · 2026 · PMID 42032753 · DOI 10.1186/s13045-026-01803-9
Antibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules.
Katoh M, Loriot Y, Nakayama I, Hamada A, et al · · 2025 · PMID 41164107 · DOI 10.3389/fmmed.2025.1661016

Verify or expand the search:

Other trials of JS107

Trials testing the same drug.

NCT05657418 — A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer · Phase 1 · terminated

Other recruiting trials for Advanced Solid Tumors

Currently open trials in the same condition.

NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Shanghai Junshi Bioscience Co., Ltd. trials

Trials by the same sponsor.

NCT07503756 — JS212 Combination Therapies in Metastatic Colorectal Cancer · Phase 2 · not yet recruiting
NCT07480733 — Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors · Phase 2 · not yet recruiting
NCT07484724 — A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Ce · Phase 2 · not yet recruiting
NCT07518160 — JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study · Phase 2 · not yet recruiting
NCT07309276 — A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05502393 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Junshi Bioscience Co., Ltd.
Last refreshed: 16 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05502393.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing